Analysts Expect Lipocine Inc (LPCN) Will Announce Earnings of -$0.26 Per Share

Equities analysts expect Lipocine Inc (NASDAQ:LPCN) to report ($0.26) earnings per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Lipocine’s earnings. The highest EPS estimate is ($0.21) and the lowest is ($0.30). Lipocine posted earnings of ($0.16) per share during the same quarter last year, which suggests a negative year over year growth rate of 62.5%. The company is scheduled to report its next earnings report on Monday, March 5th.

On average, analysts expect that Lipocine will report full year earnings of ($1.04) per share for the current year, with EPS estimates ranging from ($1.11) to ($1.00). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.85) per share, with EPS estimates ranging from ($0.97) to ($0.63). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that cover Lipocine.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.05.

Several analysts have issued reports on the company. HC Wainwright set a $3.00 target price on Lipocine and gave the company a “buy” rating in a research note on Friday, January 12th. Canaccord Genuity reiterated a “hold” rating and issued a $2.00 price target (down from $11.00) on shares of Lipocine in a research report on Tuesday, January 9th. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $11.00 price target on shares of Lipocine in a research report on Thursday, January 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $13.50.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. P.A.W. Capital Corp purchased a new position in shares of Lipocine in the third quarter valued at $397,000. Goldman Sachs Group Inc. purchased a new position in shares of Lipocine in the second quarter valued at $300,000. Vanguard Group Inc. grew its position in shares of Lipocine by 39.7% in the second quarter. Vanguard Group Inc. now owns 546,027 shares of the specialty pharmaceutical company’s stock valued at $2,195,000 after purchasing an additional 155,110 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of Lipocine by 18.2% in the second quarter. Ameriprise Financial Inc. now owns 155,600 shares of the specialty pharmaceutical company’s stock valued at $626,000 after purchasing an additional 24,000 shares in the last quarter. Finally, Federated Investors Inc. PA grew its position in Lipocine by 9.2% during the second quarter. Federated Investors Inc. PA now owns 88,083 shares of the specialty pharmaceutical company’s stock worth $354,000 after buying an additional 7,429 shares in the last quarter. Institutional investors own 22.06% of the company’s stock.

Shares of Lipocine (NASDAQ LPCN) traded down $0.07 during trading on Friday, reaching $1.36. The company had a trading volume of 1,055,764 shares, compared to its average volume of 1,002,462. The company has a market capitalization of $28.83, a price-to-earnings ratio of -1.43 and a beta of 1.93. Lipocine has a 1-year low of $1.30 and a 1-year high of $5.33.

COPYRIGHT VIOLATION WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/01/21/analysts-expect-lipocine-inc-lpcn-will-announce-earnings-of-0-26-per-share.html.

About Lipocine

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Get a free copy of the Zacks research report on Lipocine (LPCN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lipocine (NASDAQ:LPCN)

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply